2. Search Result
Search Result
Results for "

Tyrosine_kinase-IN-1

" in MedChemExpress (MCE) Product Catalog:

25

Inhibitors & Agonists

1

Fluorescent Dyes

1

Biochemical Assay Reagents

3

Peptides

1

Natural
Products

3

Isotope-Labeled Compounds

1

GMP Molecules

Cat. No. Nom du produit Target Áreas de investigación Chemical Structure
  • HY-125017
    Bozitinib
    1 Publications Verification

    PLB-1001; CBT-101; VebreltINib

    		 c-Met/HGFR Cancer
    Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily .
    Bozitinib
  • HY-15728
    Radotinib
    1 Publications Verification

    IY-5511

    		 Bcr-Abl Apoptosis STAT JAK Prion Protein Infection Neurological Disease Cancer
    Radotinib (IY-5511) is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC50 of 34 nM. Radotinib has anti-prion and anti-tumor activities. Radotinib can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases [1] .
    Radotinib
  • HY-10408
    Ki20227
    4 Publications Verification

    		 c-Fms VEGFR c-Kit PDGFR Inflammation/Immunology
    Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC50s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction [1].
    Ki20227
  • HY-100315
    XL 999

    TyrosINe kINase-IN-1

    		 VEGFR PDGFR FGFR Cardiovascular Disease Cancer
    XL999 is a multi-target tyrosine kinase inhibitor. XL999 has IC50 values for KDR, Flt-1, FGFR1 and PDGFRα of 4 nM, 20 nM, 4 nM and 2 nM, respectively. XL999 can be used in the research of cancer [1].
    XL 999
  • HY-112412
    PDGFR Tyrosine kinase-IN-1

    		PDGFR Neurological Disease
    PDGFR Tyrosine kinase-IN-1, a multikinase inhibitor, inhibits PDGFR, EGFR, FGFR, PKA, and PKC, respectively. PDGFR Tyrosine kinase-IN-1 can be used for the research of amyotrophic lateral sclerosis [1].
    PDGFR Tyrosine kinase-IN-1
  • HY-117718
    AG957

    TyrphostIN AG957; NSC 654705

    		 Bcr-Abl Cancer
    AG957 (Tyrphostin AG957;NSC 654705) is a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity . AG957 is a bcr/abl kinase inhibitor with an IC50 of 2.9 μM for p210 bcr/abl autokinase activity .
    AG957
  • HY-10331S
    Regorafenib-d3

    BAY 73-4506-d3

    		 VEGFR Autophagy PDGFR Raf RET Cancer
    Regorafenib-d3 (BAY 73-4506-d3) is a deuterium labeled Regorafenib (HY-10331). Regorafenib is a multi-targeted receptor tyrosine kinase inhibitor .
    Regorafenib-d3
  • HY-50895G
    Gefitinib

    ZD1839

    		 EGFR Autophagy Apoptosis Cancer
    Gefitinib (ZD1839) (GMP) is Gefitinib (HY-50895) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Gefitinib is a potent, selective and orally active EGFR tyrosine kinase inhibitor .
    Gefitinib
  • HY-W002950
    Erlotinib lactam impurity

    		Drug Intermediate Cancer
    Erlotinib lactam impurity (compound 7a) is a precursor of the tyrosine kinase inhibitor .
    Erlotinib lactam impurity
  • HY-159840
    Fanregratinib

    		FGFR Cancer
    Fanregratinib is a fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor .
    Fanregratinib
  • HY-15656S
    Ceritinib-d7

    LDK378 d7

    		 Isotope-Labeled Compounds Anaplastic lymphoma kinase (ALK) Insulin Receptor IGF-1R Metabolic Disease Inflammation/Immunology Cancer
    Ceritinib (LDK378)-d7 is a deuterium labeled Ceritinib (HY-15656). Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor . Ceritinib is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. Ceritinib also inhibits IGF-1R, InsR, and STK22D with IC50 values of 8, 7, and 23 nM, respectively. Ceritinib shows great antitumor potency [1] .
    Ceritinib-d7
  • HY-P2547A
    Tyrosine Kinase Peptide 1 acetate

    		Src Others
    Tyrosine Kinase Peptide 1 (acetate) is a control substrate peptide for c-Src assay [1].
    Tyrosine Kinase Peptide 1 acetate
  • HY-P2547
    Tyrosine Kinase Peptide 1

    		Src Others
    Tyrosine Kinase Peptide 1 is a control substrate peptide for c-Src assay [1].
    Tyrosine Kinase Peptide 1
  • HY-149895
    Syk-IN-7

    		Syk Cancer
    Syk-IN-7 (compound 17) is an inhibitor of spleen tyrosine kinase (SYK) .
    Syk-IN-7
  • HY-147612
    Tyrosine kinase-IN-4

    		c-Met/HGFR Cancer
    Tyrosine kinase-IN-4 (EXAMPLE 107) is a protein tyrosine kinase inhibitor .
    Tyrosine kinase-IN-4
  • HY-W062695
    (R)-Acalabrutinib

    (R)-ACP-196

    		 Btk Cancer
    (R)-Acalabrutinib ((R)-ACP-196) is the enantiomer of Acalabrutinib (HY-17600). (R)-Acalabrutinib is an inhibitor for Bruton’s tyrosine kinase (BTK) .
    (R)-Acalabrutinib
  • HY-135742
    Lenvatinib N-oxide

    LenvatINib impurity 10

    		 VEGFR Cancer
    Lenvatinib N-Oxide (Lenvatinib impurity 10) is the impurity of Lenvatinib (HY-10981). Lenvatinib (E7080) is an orally active, multi-targeted tyrosine kinase inhibitor .
    Lenvatinib N-oxide
  • HY-P1776
    [pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153)

    		Insulin Receptor Metabolic Disease
    [pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153) binds to insulin and can be used as insulin receptor tyrosine kinase substrates .
    [pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153)
  • HY-N12041
    Axl-IN-16

    		TAM Receptor HIF/HIF Prolyl-Hydroxylase Cancer
    Axl-IN-16 is a dual inhibitor of Axl/HIF. Axl-IN-16 induces fruiting body formation of Flammulina velutipes. Axl-IN-16 inhibits hypoxia-inducible factor activity and receptor tyrosine kinase expression .
    Axl-IN-16
  • HY-117718R
    AG957 (Standard)

    TyrphostIN AG957 (Standard); NSC 654705 (Standard)

    		 Bcr-Abl Reference Standards Cancer
    AG957 (Standard) is the analytical standard of AG957. This product is intended for research and analytical applications. AG957 (Tyrphostin AG957;NSC 654705) is a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity . AG957 is a bcr/abl kinase inhibitor with an IC50 of 2.9 μM for p210bcr/abl autokinase activity .
    AG957 (Standard)
  • HY-15728S
    Radotinib-d6

    IY-5511-d6

    		 Isotope-Labeled Compounds Bcr-Abl Apoptosis STAT JAK Prion Protein Infection Neurological Disease Cancer
    Radotinib-d6 is deuterium labeled Radotinib (HY-15728). Radotinib (IY-5511) is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC50 of 34 nM. Radotinib has anti-prion and anti-tumor activities. Radotinib can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases [1] .
    Radotinib-d6
  • HY-123726
    ErbB-1/ErbB-2 tyrosine kinase-IN-1

    		EGFR Cancer
    ErbB-1/ErbB-2 tyrosine kinase-IN-1 is a dual ErbB-1/ErbB-2 tyrosine kinase inhibitor with IC50 values of 0.027 μM and 0.026 μM. ErbB-1/ErbB-2 tyrosine kinase-IN-1 targets the ATP binding region of ErbB-1 and ErbB-2 tyrosine kinases. ErbB-1/ErbB-2 tyrosine kinase-IN-1 inhibits cancer cells proliferation [1].
    ErbB-1/ErbB-2 tyrosine kinase-IN-1
  • HY-100315R
    XL 999 (Standard)

    TyrosINe kINase-IN-1 (Standard)

    		 VEGFR Reference Standards PDGFR FGFR Cardiovascular Disease Cancer
    XL 999 (Standard) is the analytical standard of XL 999 (HY-100315). This product is intended for research and analytical applications. XL999 is a multi-target tyrosine kinase inhibitor. XL999 has IC50 values for KDR, Flt-1, FGFR1 and PDGFRα of 4 nM, 20 nM, 4 nM and 2 nM, respectively. XL999 can be used in the research of cancer [1].
    XL 999 (Standard)
  • HY-179460
    Radotinib dihydrochloride

    IY-5511 dihydrochloride

    		 Bcr-Abl Apoptosis STAT JAK Prion Protein Neurological Disease Cancer
    Radotinib (IY-5511) dihydrochloride is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC50 of 34 nM. Radotinib dihydrochloride has anti-prion and anti-tumor activities. Radotinib dihydrochloride can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib dihydrochloride can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases [1] .
    Radotinib dihydrochloride
  • HY-10408R
    Ki20227 (Standard)

    		Reference Standards c-Fms VEGFR c-Kit PDGFR Inflammation/Immunology
    Ki20227 (Standard) is the analytical standard of Ki20227 (HY-10408). This product is intended for research and analytical applications. Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC50s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction [1].
    Ki20227 (Standard)

Demande en ligne

Your information is safe with us. * Required Fields.

Civilité

  

Country or Region *

Nom du demandeur *

 

Nom de l'organisation *

Department *

     

Adresse e-mail *

 

Nom du produit *

Cat. No.

  

Requested quantity *

Numéro de téléphone *

     

Remarques

Demande en ligne

Inquiry Information

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent: